UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 450

Sortiert nach

1.6 Exenatide BID vs. Insulin Lispro TIDM Added to Titrated Insulin Glargine QD in Metformin-Treated T2DM Patients Resulted in Similar Glycemic Control but Weight Loss and Less Hypoglycemia: The 4B Study (70-OR)

Nederlands Tijdschrift voor Diabetolog, 2013-09, Vol.11 (3), p.79-79

2013

Link zum Volltext

Verfügbarkeit prüfen

1.7 Efficacy and Safety of Dulaglutide vs. Sitagliptin after 52 Weeks in Type 2 diabetes (AWARD-5) (71-OR)

Nederlands Tijdschrift voor Diabetolog, 2013-09, Vol.11 (3), p.79-80

2013

Link zum Volltext

Verfügbarkeit prüfen

12 - Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial

Canadian journal of diabetes, 2017-10, Vol.41 (5), p.S5-S5

2017

Link zum Volltext

Verfügbarkeit prüfen

342-P: Effects of Sitagliptin on Hypoglycemic Episodes and Counterregulation in Type 2 Diabetic Patients Tightly Titrated with Insulin Glargine

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Link zum Volltext

Verfügbarkeit prüfen

55-OR: Oral Semaglutide vs. Liraglutide and Placebo in T2D: PIONEER 4

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

58-OR: The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to a Selective Long-Acting GLP-1 Receptor Agonist

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

993-P: A 12-Week, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Three Dose-Escalation Algorithms of Tirzepatide, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

A1C Improvement with Liraglutide Evaluated by Baseline BMI

Canadian journal of diabetes, 2013-10, Vol.37, p.S35-S36

2013

Link zum Volltext

Verfügbarkeit prüfen

Abbildungsnachweis

Therapie-Handbuch Onkologie und Hämatologie, 2022, p.XV-XVI

2022

Link zum Volltext

Verfügbarkeit prüfen

Abkürzungen

Therapie-Handbuch Onkologie und Hämatologie, 2022, p.XI-XIV

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 14477: Adolescent Lipoprotein Subclass Profile: Reference Ranges, Comparison to Adult, and Association With Carotid Intima-media Thickness

Circulation (New York, N.Y.), 2020-11, Vol.142 (Suppl_3 Suppl 3), p.A14477-A14477

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 14529: Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes and Prior Coronary Artery Bypass Graft (CABG) Surgery: A Sub-Analysis of the LEADER Trial

Circulation (New York, N.Y.), 2018-11, Vol.138 (Suppl_1 Suppl 1), p.A14529-A14529

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract #809: Effects of Exenatide on First- and Second-Phase Insulin Secretion in Response to Intravenous Administration of Glucose in Patients with Type 2 Diabetes

Endocrine practice, 2005-03, Vol.11, p.18

2005

Link zum Volltext

Verfügbarkeit prüfen

Accurate Measurements of Gastric Emptying and Gastrointestinal Symptoms in the Evaluation of Glucagon-like Peptide-1 Receptor Agonists

Annals of internal medicine, 2023-11, Vol.176 (11), p.1542

2023

Link zum Volltext

Verfügbarkeit prüfen

Acute effects of linagliptin on intact and total glucagon‐like peptide‐1 and gastric inhibitory polypeptide levels in insulin‐dependent type 2 diabetes patients with and without moderate renal impairment

Diabetes, obesity & metabolism, 2022-05, Vol.24 (5), p.806-815

2022

Link zum Volltext

Verfügbarkeit prüfen

Adding Liraglutide to Oral Antidiabetic Drug Monotherapy: Efficacy and Weight Benefits

Postgraduate medicine, 2009-05, Vol.121 (3), p.5-15

2009

Link zum Volltext

Verfügbarkeit prüfen

Addition of a dipeptidyl peptidase‐4 inhibitor, sitagliptin, to ongoing therapy with the glucagon‐like peptide‐1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2017-02, Vol.19 (2), p.200-207

2017

Link zum Volltext

Verfügbarkeit prüfen

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

The journal of clinical endocrinology and metabolism, 1993-04, Vol.76 (4), p.912-917

1993

Link zum Volltext

Verfügbarkeit prüfen

α-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients

Diabetic medicine, 2005-04, Vol.22 (4), p.470-476

2005

Link zum Volltext

Verfügbarkeit prüfen

Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial

Diabetes care, 2017-07, Vol.40 (7), p.966-972

2017

Link zum Volltext

Verfügbarkeit prüfen

Anemia in Patients with Type 1 and Type 2 Diabetes

Diabetes (New York, N.Y.), 2005-06, Vol.54, p.A204

2005

Link zum Volltext

Verfügbarkeit prüfen

Another milestone in the evolution of GLP-1-based diabetes therapies

Nature medicine, 2021-06, Vol.27 (6), p.952-953

2021

Link zum Volltext

Verfügbarkeit prüfen

Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia

Journal of lipid research, 1998-03, Vol.39 (3), p.658-669

1998

Link zum Volltext

Verfügbarkeit prüfen

Apolipoprotein E2 (Arg136 → Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia1

Journal of lipid research, 1998-03, Vol.39 (3), p.658-669

1998

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 450

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(397)
Mit Volltextzugriff
(406)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(292)
Life Sciences & Biomedicine
(275)
Humans
(266)
Endocrinology & Metabolism
(181)
Male
(144)
Diabetes
(138)
Female
(128)
Middle Aged
(110)
Diabetes Mellitus, Type 2 - Drug Therapy
(105)
Biological And Medical Sciences
(97)
Medical Sciences
(85)
Adult
(84)
Diabetes Mellitus
(79)
Aged
(75)
Glucose
(75)
Type 2 Diabetes
(72)
Insulin
(62)
Hypoglycemic Agents - Therapeutic Use
(60)
Internal Medicine
(60)
Endocrinopathies
(59)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

1.6 Exenatide BID vs. Insulin Lispro TIDM Added to Titrated Insulin Glargine QD in Metformin-Treated T2DM Patients Resulted in Similar Glycemic Control but Weight Loss and Less Hypoglycemia: The 4B Study (70-OR)

1.7 Efficacy and Safety of Dulaglutide vs. Sitagliptin after 52 Weeks in Type 2 diabetes (AWARD-5) (71-OR)

12 - Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial

342-P: Effects of Sitagliptin on Hypoglycemic Episodes and Counterregulation in Type 2 Diabetic Patients Tightly Titrated with Insulin Glargine

55-OR: Oral Semaglutide vs. Liraglutide and Placebo in T2D: PIONEER 4

58-OR: The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to a Selective Long-Acting GLP-1 Receptor Agonist

993-P: A 12-Week, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Three Dose-Escalation Algorithms of Tirzepatide, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes

A1C Improvement with Liraglutide Evaluated by Baseline BMI

Abbildungsnachweis

Abkürzungen

Abstract 14477: Adolescent Lipoprotein Subclass Profile: Reference Ranges, Comparison to Adult, and Association With Carotid Intima-media Thickness

Abstract 14529: Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes and Prior Coronary Artery Bypass Graft (CABG) Surgery: A Sub-Analysis of the LEADER Trial

Abstract #809: Effects of Exenatide on First- and Second-Phase Insulin Secretion in Response to Intravenous Administration of Glucose in Patients with Type 2 Diabetes

Accurate Measurements of Gastric Emptying and Gastrointestinal Symptoms in the Evaluation of Glucagon-like Peptide-1 Receptor Agonists

Acute effects of linagliptin on intact and total glucagon‐like peptide‐1 and gastric inhibitory polypeptide levels in insulin‐dependent type 2 diabetes patients with and without moderate renal impairment

Adding Liraglutide to Oral Antidiabetic Drug Monotherapy: Efficacy and Weight Benefits

Addition of a dipeptidyl peptidase‐4 inhibitor, sitagliptin, to ongoing therapy with the glucagon‐like peptide‐1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

α-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients

Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial

Analyzing illumina gene expression microarray data from different tissues: methodological aspects of data analysis in the metaxpress consortium

Anemia in Patients with Type 1 and Type 2 Diabetes

Another milestone in the evolution of GLP-1-based diabetes therapies

Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia

Apolipoprotein E2 (Arg136 → Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia1

Suchergebnisse filtern